Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Zhuhai Yufan Biotechnologies patents CDK inhibitors

Oct. 30, 2020

Lynk Pharmaceuticals discloses new JAK inhibitors

Oct. 30, 2020

Six months of therapy completed in low-dose cohort of phase I/II brain cancer study of NOX-A12

Oct. 30, 2020

Scandion Oncology initiates phase Ib pancreatic cancer study of SCO-101

Oct. 29, 2020

NMBS-2: a selective and potent HPK1 inhibitor for enhancing antitumor immunity

Oct. 29, 2020

AUR-102: a potent and selective CDK7 inhibitor for cancer treatment

Oct. 29, 2020

Recruitment completed in phase III FORTRESS study of balixafortide

Oct. 29, 2020

Australian regulatory authorities approve phase I study of APL-1501

Oct. 29, 2020

CDK2/cyclin E inhibitors synthesized by Incyte

Oct. 29, 2020

Aligos Therapeutics presents new PRMT5 inhibitors

Oct. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...